An open-label, phase 1 / 2 study to evaluate the safety, pharmacokinetics and preliminary anti-tumour activity of Englumafusp Alfa [RO7227166, A CD19 targeted 4-1BB ligand] in combination with Obinutuzumab and in combination with Glofitamab following a pre-treatment of Obinutuzumab administered in participants with relapsed/refractory B-cell Non-Hodgkin’s Lymphoma (NCT04077723)
BP41072
This trial is Currently recruiting
Registration number NCT04077723
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Dr Shafqat Inam
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTRIf you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.